Nymox Pharmaceutical has announced that an interim safety analysis of its ongoing multicenter Phase II trial of NX-1207 has revealed no serious side-effects. NX-1207 is the company's lead drug candidate for the treatment of benign prostatic hyperplasia.
In completed Phase I and II trials, subjects treated with NX-1207 showed statistically significant overall mean symptom improvement and shrinkage in prostate size. There were no serious adverse events from the drug in these trials. Subjects that were followed for up to two years post-treatment showed even further statistically significant symptom improvement.